ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference

ObsEva announced on March 3, 2021, that its management team will provide a corporate update during the H.C.

Rhea-AI Summary

ObsEva announced on March 3, 2021, that its management team will provide a corporate update during the H.C. Wainwright Global Life Sciences Conference, held on March 9-10, 2021. The presentation will be available on-demand via the conference portal starting at 7 a.m. EST on March 9. ObsEva focuses on developing novel therapies to enhance women's reproductive health, with a late-stage clinical pipeline targeting endometriosis, uterine fibroids, and preterm labor. The company is publicly traded on NASDAQ under the symbol OBSV.

Argus Publication session

-5.64% session move Open Argus

Details

News Market Reaction – OBSV

In the trading session that priced this news, OBSV declined 5.64%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021.

ObsEva webcast link [here]

The presentation and archived webcast will also be accessible under “Events Calendar” in the investors section of ObsEva’s [website].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602

###

 

 

Attachment

• Press Release in Pdf

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ObsEva present at the H.C. Wainwright Global Life Sciences Conference?

ObsEva will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

How can I access ObsEva's presentation from the conference?

The presentation will be available on-demand starting at 7 a.m. EST on March 9, 2021, through the H.C. Wainwright conference portal.

What are ObsEva's main focuses in women's reproductive health?

ObsEva is focused on developing therapies for endometriosis, uterine fibroids, and preterm labor.

What is the stock symbol for ObsEva?

ObsEva trades under the stock symbol OBSV on NASDAQ.

Where can I find more information about ObsEva?

More information about ObsEva can be found on their official website at www.ObsEva.com.